KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities (2024 - 2025)

Recursion Pharmaceuticals' Other Non-Current Liabilities history spans 2 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 56.04% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 56.04%, while the annual FY2025 figure was $2.1 million, 56.04% down from the prior year.
  • Other Non-Current Liabilities reached $2.1 million in Q4 2025 per RXRX's latest filing, up from $1.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4.8 million in Q1 2025 to a low of $1.0 million in Q3 2025.